scholarly journals Inhibition of Stat3 by a Small Molecule Inhibitor Slows Vision Loss in a Rat Model of Diabetic Retinopathy

2017 ◽  
Vol 58 (4) ◽  
pp. 2095 ◽  
Author(s):  
Phillip A. Vanlandingham ◽  
Didier J. Nuno ◽  
Alexander B. Quiambao ◽  
Eric Phelps ◽  
Ronald A. Wassel ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Small Molecule ◽  
Rat Model ◽  
Vision Loss ◽  
Small Molecule Inhibitor ◽  
Molecule Inhibitor

The effect of the CXCR7 inhibitor CCX662 on survival in the ENU rat model of glioblastoma.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e13580-e13580
Author(s):  
Karen Ebsworth ◽  
Matthew J. Walters ◽  
Linda S Ertl ◽  
Yu Wang ◽  
Penglie Zhang ◽  
...  
Keyword(s):  
Survival Time ◽  
Small Molecule ◽  
Rat Model ◽  
Dose Range ◽  
Safety Margin ◽  
Small Molecule Inhibitor ◽  
Therapeutic Effects ◽  
Range Finding ◽  
Molecule Inhibitor ◽  
Endothelial Migration

e13580 Background: Glioblastoma (GBM) is the most common form of malignant brain cancer. Despite aggressive therapy, consisting of radiotherapy, surgical resection, and chemotherapeutic treatment, mean survival from time of diagnosis remains little more than one year. The chemokine receptor CXCR7 is highly expressed on both human glioma cells and tumor-associated vasculature, and may play a key role in tumor growth and survival. Methods: The in vitro activity of the CXCR7 antagonist CCX662 was determined using radioligand binding assays and trans-endothelial migration assays. The therapeutic effects of CCX662 were investigated in the ENU-induced rat model of GBM in combination with radiotherapy. Results: CCX662 is a highly potent and selective small molecule inhibitor of CXCR7. CCX662 inhibits the binding of 125I-CXCL12 to CXCR7 with an IC50 of 9 nM in buffer, and displays minimal serum shift with an IC50 of 18 nM in 100% human serum. CCX662 inhibits the CXCR4-directed trans-endothelial migration of CXCR4+/CXCR7+ NC37 cells towards CXCL12 (SDF1) with an IC50 of 106 nM. CCX662 also potently inhibits binding of 125I-CXCL12 to rat CXCR7 in the presence of 100% rat serum with an IC50 of 14 nM. In vivo inhibition of CXCR7 with CCX662, in concert with radiotherapy, results in a significant extension of survival time in the ENU-induced rat model of GBM. The median survival time for rats (reflective of GBM tumor progression) treated with the combination of irradiation and CCX662 was 234 days compared with 160 days for untreated rats (p<0.01) or compared with 174 days for rats given irradiation plus vehicle (p<0.01). As expected for a non-cytotoxic drug, dose-range finding 14-day toxicology studies in rats and dogs have demonstrated large (> 10 and 25-fold, respectively) safety margin relative to highly effective levels of the drug. Conclusions: CCX662 is a highly selective and potent small molecule inhibitor of CXCR7 with profound, therapeutic benefit in an aggressive rodent model of GBM. These data indicate that inhibition of CXCR7, using CCX662, may be a promising strategy for the treatment of glioblastoma.

Sign in / Sign up

Export Citation Format

Share Document